Chardan Capital Maintains Buy on CervoMed, Raises Price Target to $21

Benzinga Newsdesk www.benzinga.com Positive 82.4%

Neg 0% Neu 0% Pos 82.4%

Chardan Capital analyst Daniil Gataulin maintains CervoMed (NASDAQ:CRVO) with a Buy and raises the price target from $15 to $21.